-
5-Methyl-CTP for Modified mRNA Synthesis
2026-08-26
5-Methyl-CTP is a 5-methyl modified cytidine triphosphate used as a substrate for in vitro transcription of modified mRNA. Its product specifications support controlled reagent handling, while published RNA-modification literature indicates that biological effects depend on transcript design, incorporation, purification, and delivery context.
-
Recombinant Human Oncostatin M: Assay Guide
2026-08-26
Learn how Recombinant Human Oncostatin M (E.coli, Tag Free, Lyophilized), SKU P1045, can address variability in viability, proliferation, and cytokine-release assays. This scenario-based guide covers assay interpretation, reconstitution, controls, cross-model comparisons, and practical vendor-selection criteria.
-
Tetrahydromagnolol for CB2 Signaling Workflows
2026-08-25
Tetrahydromagnolol combines potent peripheral CB2 agonism with GPR55 antagonism, enabling pathway-resolved cannabinoid receptor research rather than single-endpoint screening. This guide translates those properties into receptor, inflammatory, migration, and GPCR-to-cytoskeleton workflows while clearly separating established evidence from testable applications.
-
TUDCA in ER Stress and Metabolic Research
2026-08-25
Tauroursodeoxycholic Acid, or TUDCA, is a taurine-conjugated bile acid derivative used to study ER stress, apoptosis, mitochondrial injury, and metabolic dysfunction. Its strongest value is as a hypothesis-testing chemical chaperone, not as a pathway-specific substitute for genetic or pharmacological validation.
-
Targeted EPO mRNA Nanoparticles for Spinal Cord Repair
2026-08-24
A 2026 Materials Today Bio study developed mannose-modified lipid nanoparticles to deliver erythropoietin mRNA to CD206-enriched inflammatory macrophages and microglia after spinal cord injury. In mice, localized EPO production reduced neuroinflammation and ferroptosis-associated damage while improving axonal preservation and motor recovery, providing a mechanistically informed framework for targeted mRNA nanotherapy.
-
CDK9 inhibitor A3294: Protocol and QC Guide
2026-08-24
CDK9 inhibitor A3294 provides selective CDK9 modulation for transcription elongation and defined HIV-1 propagation studies, with a reported IC50 of 39 nM and limited activity against the listed CDK family members. It is intended for focused pathway experiments rather than pan-CDK profiling, general cell cycle regulation, or long-term storage of working solutions.
-
InstaBlue Protein Stain Solution for Proteomics
2026-08-23
InstaBlue Protein Stain Solution streamlines protein electrophoresis analysis with fixation-free visualization in approximately 5 minutes and reported sensitivity down to 5 ng. Its methanol- and acetic acid-free formulation is especially useful when gel bands must move efficiently from biomedical research protein visualization to quantification or mass spectrometry.
-
CUX2 Neuron Loss and DNA Damage in Neuroinflammation
2026-08-22
The reference study identifies accumulated DNA damage and insufficient double-strand-break repair as a mechanistic basis for the selective loss of CUX2-positive layer 2/3 excitatory neurons in multiple sclerosis and mouse neuroinflammation models. Its human-to-animal-to-cellular design links interferon-γ-driven oxidative stress with neuronal vulnerability and provides a framework for studying cell-type-specific degeneration.
-
NHS-Biotin: Reliable Protein Labeling in Cell Assays
2026-08-21
NHS-Biotin (SKU A8002) provides a practical route to stable amine-reactive labeling for antibody, protein, surface, and intracellular workflows that support cell-based assay interpretation. This scenario-driven guide explains chemistry, compatibility, handling, data normalization, and vendor-selection considerations for reproducible protein detection and purification.
-
Annexin V-APC/7-AAD Apoptosis Kit Workflow
2026-08-20
Build a rapid dual-parameter workflow that separates viable, early apoptotic, late apoptotic, and membrane-compromised cells. The Annexin V-APC/7-AAD Apoptosis Kit is especially useful for linking immune-checkpoint perturbation with tumor-cell and T-cell fate in cancer models.
-
Rab26 Deficiency Disrupts SERT Trafficking in Mice
2026-08-20
The reference study links Rab26 loss to depression- and anxiety-like behaviors, cognitive impairment, altered synaptic physiology, and defective serotonin transporter (SERT) trafficking. Its central innovation is the identification of a Rab26–SERT regulatory pathway connecting membrane transport, autophagic degradation, serotonin uptake, and behavioral phenotypes.
-
Sulfo-NHS-SS-Biotin for Surface Protein Trafficking
2026-08-19
Sulfo-NHS-SS-Biotin combines cell-impermeant surface labeling with a cleavable disulfide linker, making it useful for tracking membrane delivery and recovering labeled proteins. This practical guide connects reversible biotinylation to invadopodium studies of MT1-MMP, EGFR, Munc18c, and syntaxin4 while emphasizing workflow control and troubleshooting.
-
TH287 Sensitizes CRPC Cells to Radiation
2026-08-19
A 2026 study found that TH287 enhanced ionizing-radiation responses in PC-3 and DU-145 castration-resistant prostate cancer cells, with the strongest effect when radiation followed inhibitor exposure by 12 hours. The work adds a practical timing variable to MTH1-based radiosensitization and links the combination to increased apoptosis and cell-cycle disruption.
-
LY2228820: p38 MAP kinase inhibitor workflows
2026-08-18
LY2228820 enables controlled inhibition of p38α/β signaling across biochemical, inflammatory, and cancer research workflows. Its nanomolar biochemical potency, formulation flexibility, and compatibility with phospho-MK2, cytokine, and apoptosis readouts support mechanism-focused experiments rather than single-endpoint screening.
-
Gut-Brain Cholinergic Signaling in Seizure Control
2026-08-18
Jia et al. identify a gut-vagus-brain cholinergic circuit through which Bacteroides fragilis suppresses seizures in mouse models and improves outcomes in a pediatric refractory epilepsy trial. The study connects microbial composition, colonic ChAT-positive cells, vagal transmission, and acetylcholine receptor activation, providing a mechanistic framework for microbiota-based antiseizure research.